Multiple Myeloma: Multiplying Therapies

摘要

Multiple myeloma must have among the most, if not the most, FDA approvals for any one malignancy. If the four liposomal doxorubicin approvals are counted separately, there are 21 FDA approvals (1). Such a list is remarkable and does not include combinations of these agents. The 5-year survival rates, which have almost doubled over the last decade, are now pegged at 48.5% and will likely be higher with the new agents approved by the FDA in 2015 (Fig. 1).